Construction of necroptosis-related lncRNA risk model of pancreatic cancer based on bioinformatics

doi:10.16138/j.1673-6087.2025.03.08

Abstract

Abstract:

Objective To construct a prognostic risk model for pancreatic cancer based on necroptosis-related long non-coding RNA (NRL). Methods The gene expression data and clinical data were from the Cancer Genome Atlas (TCGA) and GTEx databases, including 171 normal pancreas and 178 pancreatic cancer samples. LASSO regression and Cox regression analysis were used to identify NRL associated with pancreatic cancer prognosis to construct the risk model. The predictive value of the model was evaluated using receiver operating characteristic (ROC) curves and validated in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) database. Gene enrichment analysis, immune infiltration analysis, and chemotherapy drug sensitivity analysis were also conducted. Results The eight NRL (LINC01559, TMEM161B-AS1, AL157392.3, AC099850.3, AC136475.3, AL162274.2, MIR217HG, UNC5B-AS) were screened for constructing the NRL risk model. Survival analysis indicated that patients in the high-risk group had poorer prognosis (P<0.001). ROC curves were both >0.6, confirming the accuracy of the model. Regression analysis confirmed that the model was an independent prognostic factor for pancreatic cancer patients (P<0.05), and CPTAC data showed that the effectiveness of this model was good. Additionally, there were significant differences (P<0.05) in pathway enrichment, immune cell infiltration, tumor mutation burden, expression of immune checkpoints, and chemotherapy drug sensitivity between the high risk and low risk groups. Conclusions The risk model constructed based on 8 NRL can effectively predicts the prognosis of pancreatic cancer, and strongly correlated with the level of immune infiltration in pancreatic cancer which may provide new reference for immunotherapy and chemotherapy drug selection.

Key words: Pancreatic cancer, lncRNA, Necroptosis, Bioinformatics, TCGA, Risk model

CLC Number:

R735.9

YANG Ziyun, YAO Weiyan. Construction of necroptosis-related lncRNA risk model of pancreatic cancer based on bioinformatics[J]. Journal of Internal Medicine Concepts & Practice, 2025, 20(03): 232-241.

Figures/Tables 8

Figure 1

Figure 2

Table 1

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

References 36

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1):7-33..
[2]	Huang X, Ding L, Liu X, et al. Regulation of tumor microenvironment for pancreatic cancer therapy[J]. Biomaterials, 2021,270:120680.
[3]	Gong Y, Fan Z, Luo G, et al. The role of necroptosis in cancer biology and therapy[J]. Mol Cancer, 2019, 18(1):100. doi: 10.1186/s12943-019-1029-8 pmid: 31122251
[4]	Chen X, Zeh HJ, Kang R, et al. Cell death in pancreatic cancer: from pathogenesis to therapy[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(11):804-823. doi: 10.1038/s41575-021-00486-6 pmid: 34331036
[5]	Ando Y, Ohuchida K, Otsubo Y, et al. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5[J]. PLoS One, 2020, 15(1):e0228015.
[6]	Zhang Y, Yue Q, Cao F, et al. Necroptosis-related lncRNA signatures determine prognosis in breast cancer patients[J]. Sci Rep, 2022, 12(1):11268. doi: 10.1038/s41598-022-15209-3 pmid: 35787661
[7]	Luo J, Peng J, Xiao W, et al. A novel necroptosis-related lncRNA signature for predicting prognosis and immune response of colon cancer[J]. Front Genet, 2022,13:984696.
[8]	Du X, Pu X, Wang X, et al. A novel necroptosis-related lncRNA based signature predicts prognosis and response to treatment in cervical cancer[J]. Front Genet, 2022,13:938250.
[9]	Ghafouri-Fard S, Fathi M, Zhai T, et al. LncRNAs: novel biomarkers for pancreatic cancer[J]. Biomolecules, 2021, 11(11):1665.
[10]	Zhao Z, Liu H, Zhou X, et al. Necroptosis-related lncRNAs: predicting prognosis and the distinction between the cold and hot tumors in gastric cancer[J]. J Oncol, 2021,2021:6718443.
[11]	Tang R, Xu J, Zhang B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity[J]. J Hematol Oncol, 2020, 13(1):110.
[12]	Xiong Y, Kong X, Fang K, et al. Establishment of a novel signature to predict prognosis and immune characteristics of pancreatic cancer based on necroptosis-related long non-coding RNA[J]. Mol Biol Rep, 2023, 50(9):7405-7419. doi: 10.1007/s11033-023-08663-3 pmid: 37452900
[13]	Mo J, Cui Z, Wang Q, et al. Integrated analysis of necroptosis-related lncRNAs for prognosis and immunotherapy of patients with pancreatic adenocarcinoma[J]. Front Genet, 2022,13:940794.
[14]	Kumari A, Sahoo J, De M. 2D-MoS2-supported copper peroxide nanodots with enhanced nanozyme activity: application in antibacterial activity[J]. Nanoscale, 2023, 15(48):19801-19814.
[15]	Shi Z, Li G, Li Z, et al. TMEM161B-AS1 suppresses proliferation, invasion and glycolysis by targeting miR-23a-3p/HIF1AN signal axis in oesophageal squamous cell carcinoma[J]. J Cell Mol, 2023, 27(4):591-592.
[16]	Ho KH, Huang TW, Shih CM, et al. Glycolysis-associated lncRNAs identify a subgroup of cancer patients with poor prognoses and a high-infiltration immune microenvironment[J]. BMC Med, 2021, 19(1):59.
[17]	Zhong F, Liu S, Hu D, et al. LncRNA AC099850.3 promotes hepatocellular carcinoma proliferation and invasion through PRR11/PI3K/AKT axis and is associated with patients prognosis[J]. J Cancer, 2022, 13(3):1048-1060. doi: 10.7150/jca.66092 pmid: 35154469
[18]	Ye J, Li H, Wei J, et al. Risk scoring system based on lncRNA expression for predicting survival in hepatocellular carcinoma with cirrhosis[J]. Asian Pac J Cancer Prev, 2020, 21(6):1787-1795.
[19]	Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5):646-674. doi: 10.1016/j.cell.2011.02.013 pmid: 21376230
[20]	Acloque H, Adams MS, Fishwick K et al. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease[J]. J Clin Invest, 2009, 119(6):1438-1449. doi: 10.1172/JCI38019 pmid: 19487820
[21]	Wei D, Wang L, Kanai M, et al. KLF4α up-regulation promotes cell cycle progression and reduces survival time of patients with pancreatic cancer[J]. Gastroenterology, 2010, 139(6):2135-2145. doi: 10.1053/j.gastro.2010.08.022 pmid: 20727893
[22]	He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha[J]. Cell, 2009, 137(6):1100-1111. doi: 10.1016/j.cell.2009.05.021 pmid: 19524512
[23]	Yamamoto K, Venida A, Yano J, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I[J]. Nature, 2020, 581(7806):100-105.
[24]	Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions[J]. Clin Cancer Res, 2006, 12(18):5423-5434. doi: 10.1158/1078-0432.CCR-06-0369 pmid: 17000676
[25]	Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression[J]. J Biomed Sci, 2019, 26(1):78. doi: 10.1186/s12929-019-0568-z pmid: 31629410
[26]	Campillo N, Falcones B, Otero J, et al. Differential oxygenation in tumor microenvironment modulates macrophage and cancer cell crosstalk: novel experimental setting and proof of concept[J]. Front Oncol, 2019,9:43.
[27]	Wang Z, Zhao J, Zhao H, et al. Infiltrating CD4/CD8 high T cells shows good prognostic impact in pancreatic cancer[J]. Int J Clin Exp Pathol, 2017, 10(8):8820-8828.
[28]	Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies[J]. Nat Rev Drug Discov, 2019, 18(3):197-218. doi: 10.1038/s41573-018-0007-y pmid: 30610226
[29]	Chen J, Wang S, Jia S, et al. Integrated analysis of long non-coding RNA and mRNA expression profile in pancreatic cancer derived exosomes treated dendritic cells by microarray analysis[J]. J Cancer, 2018, 9(1):21-31. doi: 10.7150/jca.21749 pmid: 29290766
[30]	Lawlor RT, Mattiolo P, Mafficini A, et al. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions[J]. Cancers (Basel), 2021, 13(13):3119.
[31]	Cullis J, Das S, Bar-Sagi D. Kras and tumor immunity: friend or foe?[J]. Cold Spring Harb Perspect Med, 2018, 8(9):a031849.
[32]	Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response[J]. J Cell Sci, 2020, 133(5):jcs237453.
[33]	Abu Samaan TM, Samec M, Liskova A, et al. Paclitaxel’s mechanistic and clinical effects on breast cancer[J]. Biomolecules, 2019, 9(12):789.
[34]	Bacherikov VA. Total synthesis, mechanism of action, and antitumor efficacy of camptothecin and some of its analogues[J]. Anticancer Agents Med Chem, 2022, 22(20):3438-3465.
[35]	Bongiovanni A, Liverani C, Recine F, et al. Phase-Ⅱ trials of pazopanib in metastatic neuroendocrine neoplasia (mNEN)[J]. Front Oncol, 2020,10:414.
[36]	Yuan R, Kay A, Berg WJ, et al. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy[J]. J Hematol Oncol, 2009,2:45.

特征	例数(n)	单因素分析		多因素分析
特征	例数(n)	风险比(95% CI)	P	风险比 (95% CI)	P
年龄	178	1.028 (1.006 ~ 1.050)	0.012	1.025 (1.003 ~ 1.048)	0.027
性别	178	0.897 (0.588 ~ 1.368)	0.614
女性	80	基准值（Ref）
男性	98	0.897 (0.588 ~ 1.368)	0.614
分级	176	1.377 (1.020 ~ 1.859)	0.037	1.276 (0.943 ~ 1.048)	0.114
1	31	基准值（Ref）
2	95	1.795 (0.898 ~ 3.586)	0.098
3	48	2.286 (1.101 ~ 4.748)	0.027
4	2	1.650 (0.210 ~ 12.995)	0.634
分期	175	1.422 (0.979 ~ 2.066)	0.065
2	147	基准值（Ref）		基准值（Ref）
4	4	0.886 (0.217 ~ 3.620)	0.866	0.920 (0.225 ~ 3.762)	0.907
1	21	0.305 (0.123 ~ 0.761)	0.011	0.348 (0.139 ~ 0.871)	0.054
3	3	0.668 (0.093 ~ 4.807)	0.688	0.704 (0.098 ~ 5.078)	0.728
风险评分	178	1.014 (1.007 ~ 1.021)	< 0.001	1.014 (1.006 ~ 1.022)	< 0.001